TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q1 2023
Holdings as of Mar 31, 2023, filed May 15, 2023. Long positions only; changes compare share counts with Q4 2022.
- Positions
- 22
- +1 vs. Q4 2022
- Portfolio value
- $513.0M
- −$53.6M (−9.5%) vs. Q4 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 5,141,118 | $125.1M | 24.4% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 3,631,042 | $39.2M | 7.6% | 00.0% | Unchanged | History |
| GERNGeron Corp | COM | 17,765,213 | $38.6M | 7.5% | +2,578,140+17.0% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 149,917 | $36.3M | 7.1% | −138,137−48.0% | Reduced | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $32.0M | 6.2% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 815,724 | $27.3M | 5.3% | +28,493+3.6% | Added | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 3,395,495 | $26.7M | 5.2% | 00.0% | Unchanged | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 3,048,257 | $26.6M | 5.2% | −2,857,143−48.4% | Reduced | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 3,113,600 | $26.5M | 5.2% | +780,300+33.4% | Added | – |
| JBIOJade Biosciences, Inc. | COM | 1,081,274 | $21.8M | 4.3% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 1,650,150 | $19.0M | 3.7% | +1,650,150 | New | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $17.4M | 3.4% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 663,610 | $16.9M | 3.3% | −320,000−32.5% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 2,104,875 | $13.1M | 2.5% | 00.0% | Unchanged | History |
| IMVTImmunovant, Inc. | COM | 654,853 | $10.2M | 2.0% | −200,000−23.4% | Reduced | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $8.48M | 1.7% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 350,000 | $8.33M | 1.6% | +350,000 | New | History |
| MRUSMerus N.V. | COM | 300,000 | $5.52M | 1.1% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 529,839 | $4.29M | 0.8% | −615,100−53.7% | Reduced | History |
| CABACabaletta Bio, Inc. | COM | 486,795 | $4.03M | 0.8% | 00.0% | Unchanged | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 1,250,000 | $3.92M | 0.8% | +1,250,000 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 253,069 | $1.95M | 0.4% | 00.0% | Unchanged | History |
Sold out since Q4 2022 (2)
Positions held at the end of Q4 2022 that are gone from this filing.